Skip to main content
Part of Sickle Cell Disease on Somebody To Talk To

From the archive1 min read

Vaso-Occlusive Crisis: The Future of Treating Patients With Sickle Cell Disease in Emergency Departments

Claudia Morris, MD, Childrens Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, has been studying arginine (Arg) as a therapeutic option for…

Clinical Trials and Research

About this article

Published
Last updated

Claudia Morris, MD, Childrens Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, has been studying arginine (Arg) as a therapeutic option for sickle cell disease (SCD) for years. Recently, her research revealed groundbreaking findings of the effects of Arg on patients experiencing a vaso-occlusive episode (VOE).

While statistically insignificant, results showed a clinically relevant decrease in total parenteral opioid (TPO) and a shortened time to crisis resolution in both intervention groups treated with Arg compared with placebo. Arginine is approved by the FDA for growth hormone stimulation, and because of that investigators have access to 50 years worth of safety information, despite the lack of use for treating VOEs. "The challenge right now is that we have no therapies in the emergency department to treat acute pain, outside of pain medications and IV opioids," Morris said.

 

Share